Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Alexion Pharmaceuticals (ALXN) For a detailed discussion as well as a more comprehensive list please see 12 Best Genomic Stocks To Buy … Through mid-November, it had a … Sanford C. Bernstein started coverage on shares of Alexion Pharmaceuticals in a report on Thursday, November 19th. The company is also involved in immune system research related to autoimmune diseases. Their average twelve-month price target is $91.38, predicting that the stock has a possible upside of 7.30%. CGIX stock shot up by over 100% on Wednesday but has since taken a breather. Below you can find the list of 5 best genomic stocks to buy now according to hedge funds. Genetic Engineering & Biotechnology News, including Alexion on its 2019 list of targets in biopharma and cited an analyst claim that BioMarin Pharmaceutical (NASDAQ: BMRN), itself a … It has been about a month since the last earnings report for Alexion Pharmaceuticals (ALXN Quick Quote ALXN - Free Report) .Shares have lost … Analysts' opinion: 7 Strong Buy, 6 Buy, 9 Hold, 0 Sell, 0 Strong Sell; Alexion Pharmaceuticals (ALXN, $123.47) didn't really light it up in 2020. With a $420 average price target, upside potential stands at nearly 20%. After all, BA stock has received 12“buy” ratings, with eight analysts on the sidelines. Alexion Pharmaceuticals (NASDAQ: ALXN) Alexion Pharmaceuticals is a powerhouse in the treatment of multiple rare diseases. AstraZeneca stock plunged 7.8% on Dec. 14 after the company said it would spend $39 billion to acquire Alexion Pharmaceuticals . It employs around 2,400 people worldwide. AstraZeneca expects the deal to strengthen its presence in immunology. It is the producer of Solaris, a treatment that’s currently indicated for patients with four rare conditions who previously had few or no treatment options. The proposed merger is an attempt to reduce the … The high price target for ES is $107.00 and the low price target for ES is $81.00. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in … Truist downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $155.00 to $175.00 in a research note on Wednesday, December 16th. This was after the company filed an SEC form S-4 indicating that its board approved the proposed merger with StemoniX. 4.